L3VLUP
ProSign in

DYN · LLY in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

DYNLLY
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • DYN
  • LLY
0204060202120222023202420252026
Holders and value by quarter
QuarterDYNLLY
Q3 20203 holders, $11m33 holders, $14.1bn
Q4 20201 holders, $10m29 holders, $17.3bn
Q1 20211 holders, $5.9m24 holders, $23.0bn
Q2 20212 holders, $19m24 holders, $27.8bn
Q3 20212 holders, $17m31 holders, $29.9bn
Q4 20212 holders, $21m31 holders, $34.7bn
Q1 20222 holders, $26m24 holders, $35.3bn
Q2 20221 holders, $4.6m33 holders, $42.7bn
Q3 20221 holders, $19m31 holders, $43.4bn
Q4 20222 holders, $17m31 holders, $46.6bn
Q1 20231 holders, $432k33 holders, $44.3bn
Q2 20231 holders, $4.3m37 holders, $59.6bn
Q3 20231 holders, $3.0m44 holders, $67.6bn
Q4 20231 holders, $5.8m45 holders, $73.6bn
Q1 20244 holders, $123m41 holders, $95.3bn
Q2 20245 holders, $433m43 holders, $110bn
Q3 20245 holders, $392m45 holders, $107bn
Q4 20246 holders, $287m46 holders, $93.9bn
Q1 20255 holders, $141m42 holders, $98.4bn
Q2 20253 holders, $94m43 holders, $93.2bn
Q3 20255 holders, $228m39 holders, $86.7bn
Q4 20255 holders, $291m41 holders, $123bn
Q1 20265 holders, $264m39 holders, $106bn
Q2 20263 holders, $288m44 holders, $132bn
DYN

Dyne Therapeutics Inc

Holders
6
Reported value
$287m
Buyers
4
Sellers
2

Breadth +2 among 94 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations
LLY

Eli Lilly & Co

Holders
46
Reported value
$93.9bn
Buyers
24
Sellers
23

Breadth +1 among 94 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations

Who holds both, Q4 2024

Among the 48 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only DYN (2)

Farallon Capital Management LLC, Point72 Asset Management LP

Only LLY (42)

Acadian Asset Management LLC, AllianceBernstein LP, AQR Capital Management LLC, Artisan Partners LP, Balyasny Asset Management LLC, Brevan Howard Capital Management LP, Bridgewater Associates LP, Capital Research Global Investors, Capital World Investors, Citadel Advisors LLC, Coatue Management LLC, D. E. Shaw & Co., Dodge & Cox, Egerton Capital UK LLP, Eisler Capital Management Ltd, Fidelity (FMR LLC), Freestone Grove Partners LP, GAMCO Investors Inc, Hudson Bay Capital Management LP, Invesco Ltd, Jane Street Group LLC, Lone Pine Capital LLC, Marshall Wace LLP, MFS Investment Management, Millennium Management LLC, and 17 more

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →